Abstract：
Over the past 2000 years, tuberculosis (TB) has been responsible for more deaths than any other infectious disease. In recent years, there has been a recovery of research and development (R&D) efforts focused on TB drugs. This is driven by the pressing need to combat the global spread of the disease and develop improved therapies for both drug-sensitive and drug-resistant strains. Many new TB drug candidates have recently entered clinical trials, marking the beginning of a rebirth in this area after decades of neglect. The problem is that very few of the hundreds of compounds identified each year as potential anti-TB drugs really make it to the clinical development stage. This perspective focuses on the primary obstacles and approaches involved in the development of new medications for TB. This will help medicinal chemists better understand TB drug challenges and develop novel drug candidates.
摘要：
在过去的2000年里,结核病（TB）导致的死亡人数比任何其他传染病都多。近年来,已经恢复了针对结核病药物的研发(R&D)努力。这是因为迫切需要抗击这种疾病的全球传播，并为药物敏感和耐药菌株开发改进的疗法。许多新的结核病候选药物最近进入临床试验，标志着经过几十年的忽视，这一地区开始了重生。问题在于，每年被确定为潜在抗结核药物的数百种化合物中，很少有化合物真正进入临床开发阶段。这种观点侧重于结核病新药开发中涉及的主要障碍和方法。这将有助于药物化学家更好地了解结核病药物挑战并开发新的候选药物。
